Lepu Medical Technology Co (300003) Q3 2025 earnings summary

Executive summary

• Achieved Q3 revenue of ¥1.57 billion, up 11.97% year-over-year; YTD revenue reached ¥4.94 billion, up 3.20% year-over-year.

• Q3 net profit attributable to shareholders was ¥291 million, up 176.18% year-over-year; YTD net profit was ¥982 million, up 22.35% year-over-year.

• Q3 operating cash flow was ¥1.01 billion, up 139.37% year-over-year.

Financial highlights

• Q3 EPS was ¥0.1579, up 177.02% year-over-year; YTD EPS was ¥0.5327.

• Gross margin and net margin improved, with YTD net margin up 1.15 percentage points to 22.77%.

• YTD operating cash flow reached ¥1.01 billion, up 139.37% year-over-year.

• YTD non-recurring profit was ¥41.15 million, down from ¥68.58 million last year.

Segment performance

• Cardiovascular intervention Q3 revenue: ¥554.55 million, up 7.18% year-over-year.

• Surgical anesthesia Q3 revenue: ¥95.11 million, down 37.38% year-over-year.

• In vitro diagnostics Q3 revenue: ¥64.70 million, down 17.45% year-over-year.

• Formulation sales Q3 revenue: ¥386.85 million, up 53.08% year-over-year.

• Medical services and health management Q3 revenue: ¥320.93 million, up 28.27% year-over-year.